Lybrido and Lybridos are two drugs intended to treat hypoactive sexual desire disorder (HSDD) in premenopausal women. Both are being studied in clinical trials and have not yet been approved by any regulatory agency.
Lybrido contains testosterone and sildenafil, which is the same active ingredient in the erectile dysfunction drug Viagra. It helps activate desire in the brain while improving blood flow to the genitals, helping a woman’s body respond to sexual cues.
Lybridos contains testosterone and buspirone, a type of anxiety medication. It also helps increase a woman’s desire, but does so by easing some of the inhibitory responses in the brain.
If the clinical trials are successful and the drugs are approved, they may be available in some markets by 2016.